{"gene":"BCL7A","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1996,"finding":"BCL7A was identified as a novel gene encoding a serine-rich protein of 231 amino acids with homology to the actin-binding protein caldesmon, discovered through molecular cloning of a three-way chromosomal translocation t(8;14;12) in a Burkitt lymphoma cell line where a MYC-BCL7A fusion transcript was produced with exon I of BCL7A replaced by MYC exon I.","method":"Molecular cloning, cDNA sequencing, Northern blot, sequence homology analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct molecular cloning, full cDNA sequencing, multiple breakpoints characterized; foundational discovery paper","pmids":["8605326"],"is_preprint":false},{"year":1998,"finding":"BCL7A defines a gene family (BCL7A, BCL7B, BCL7C) sharing ~90% identity in an amino-terminal domain of ~51 amino acids, with orthologs in Drosophila melanogaster, C. elegans, and Brugia malayi, but no identified protein motifs were found outside this conserved N-terminal domain.","method":"Sequence alignment, chromosomal mapping, EST homology analysis","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — sequence-based identification replicated across species and multiple family members; functional domain not yet validated biochemically","pmids":["9931421"],"is_preprint":false},{"year":2017,"finding":"BCL7A was identified as a subunit of the SWI/SNF complex in neurons; genetic deletion of BCL7A in postmitotic neurons in mice causes motor abnormalities and affects dendritic branching of Purkinje cells, while BCL7B knockout has no phenotype, demonstrating BCL7A's non-redundant role within SWI/SNF in neural function.","method":"Conditional and ubiquitous knockout mouse models, behavioral assays, neuronal morphology analysis","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean in vivo KO with specific cellular phenotype (Purkinje cell morphology, motor behavior); BCL7B double-KO rules out redundancy","pmids":["29213114"],"is_preprint":false},{"year":2020,"finding":"BCL7A functions as a tumor suppressor in DLBCL by binding to the SWI/SNF complex via its amino-terminal domain; splice site mutations in intron 1 produce a truncated BCL7A protein that fails to bind the SWI/SNF complex and cannot suppress tumor growth, while restoration of wild-type BCL7A induces transcriptomic changes in B-cell activation genes.","method":"BCL7A restoration experiments, in vitro and in vivo tumor assays, splice site mutation analysis, SWI/SNF complex binding assays, transcriptome analysis","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (in vitro/in vivo restoration, binding assay, transcriptomics), mechanistic link between truncation, complex binding failure, and loss of tumor suppression","pmids":["32576963"],"is_preprint":false},{"year":2022,"finding":"BCL7A modulates the SWI/SNF/BAF complex by stimulating genome-wide occupancy of the ATPase subunit BRG1; BCL7A is dispensable for SWI/SNF/BAF complex integrity but is essential for regulating Notch/Wnt pathway signaling and mitochondrial bioenergetics in differentiating neural progenitor cells (NPCs); pharmacological Wnt stimulation or mitochondrial biogenesis enhancement (pioglitazone) partially rescues BCL7A-deficient NPC phenotypes.","method":"BCL7A conditional knockout mice, genome-wide BRG1 occupancy (ChIP-seq), NPC differentiation assays, pharmacological rescue experiments, behavioral/cognitive testing","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional KO plus ChIP-seq occupancy data plus pharmacological rescue, multiple orthogonal methods establishing pathway position","pmids":["36305367"],"is_preprint":false},{"year":2023,"finding":"BCL7A expression is silenced in AML by promoter hypermethylation (confirmed by methylation-specific PCR, bisulfite sequencing, and 5-aza-2'-deoxycytidine treatment); restoration of BCL7A expression in AML cell lines reduces competitive growth, decreases tumor growth in xenograft models, and alters cell cycle pathways and expression of HMGCS1, H1-0, and IRF7.","method":"Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine treatment, cell competition assay, xenograft mouse model, differential expression analysis","journal":"Biomarker research","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic link between methylation-driven silencing and tumor suppressor function validated by multiple orthogonal methods including in vivo xenograft","pmids":["36941700"],"is_preprint":false},{"year":2024,"finding":"BCL7A acts as a tumor suppressor in AML and is negatively regulated post-transcriptionally by PTBP1; overexpression of BCL7A inhibits AML cell proliferation, induces apoptosis, promotes differentiation, and decreases cytarabine resistance by upregulating IRF7 and downregulating HMGCS1.","method":"BCL7A overexpression/knockdown in AML cell lines, in vivo mouse models, interaction studies with PTBP1, cell cycle/apoptosis/differentiation assays, IRF7/HMGCS1 expression analysis","journal":"Drug resistance updates","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional assays, single lab, PTBP1 interaction not fully characterized biochemically in the abstract","pmids":["39053383"],"is_preprint":false},{"year":2025,"finding":"BCL7A directly interacts with the transcription factor IRF4 (plasma cell-defining), limiting its DNA-binding activity; loss of BCL7A in multiple myeloma cells enhances IRF4-associated cytokine expression, reduces mitochondrial metabolism and reactive oxygen species levels, and promotes cell proliferation, establishing BCL7A as a tumor suppressor in MM.","method":"Whole-genome sequencing, BCL7A loss-of-function and ectopic expression in MM cell lines, in vitro and in vivo proliferation assays, protein-protein interaction assay (BCL7A–IRF4 direct interaction), RNA-seq, metabolic assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct protein-protein interaction plus in vitro/in vivo functional assays and transcriptomic/metabolic readouts; multiple orthogonal methods in a single study","pmids":["40090008"],"is_preprint":false},{"year":2026,"finding":"BCL7A contains a conserved arginine anchor in its N-terminal α-helix that is essential for chromatin remodeling activity of hSWI/SNF complexes; this anchor is required for BCL7A occupancy at target loci and chromatin accessibility/transcriptional regulation, but not for BCL7A integration into the complex; DLBCL-associated mutations in this anchor impair tumor suppressor function; mechanistically, BCL7A regulates histone displacement and works cooperatively with SMARCB1 to regulate canonical BAF (cBAF) remodeling activity.","method":"Protein structural prediction, mutagenesis of arginine anchor, in vivo and cellular tumor suppression assays, chromatin accessibility assays, transcriptional regulation analysis, ChIP occupancy assays","journal":"Protein & cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural prediction with mutagenesis validation, in vivo assays, chromatin accessibility, and mechanistic epistasis with SMARCB1; multiple orthogonal methods","pmids":["41485079"],"is_preprint":false},{"year":2025,"finding":"BCL7 proteins (including BCL7A) act as dynamic molecular tethers within the SWI/SNF ARP module, connecting it to the nucleosomal acidic patch; BCL7 proteins promote ncBAF-mediated nucleosome remodeling, and BRG1-catalyzed ATP hydrolysis triggers conformational changes that modulate BCL7-mediated histone association, as resolved by cryo-EM of ncBAF-nucleosome complexes in nucleotide-free and nucleotide-bound states. (Note: this preprint describes BCL7B specifically, but establishes a general BCL7 family mechanism.)","method":"Cryo-electron microscopy, biochemical assays, cross-linking mass spectrometry, nucleosome remodeling assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — cryo-EM structure with biochemical validation but preprint (not peer-reviewed); describes BCL7 family generally, BCL7B specifically; mechanism extrapolated to BCL7A","pmids":["bio_10.1101_2025.11.20.689410"],"is_preprint":true}],"current_model":"BCL7A is a non-catalytic subunit of the mammalian SWI/SNF/BAF chromatin remodeling complex that, via a conserved N-terminal arginine anchor, directly engages nucleosomes (interacting with the acidic patch) to stimulate genome-wide BRG1 ATPase occupancy and promote histone displacement and chromatin accessibility; its N-terminal domain also mediates a direct protein–protein interaction with IRF4 to restrict IRF4 transcriptional activity; splice-site or missense mutations disrupting this domain prevent SWI/SNF complex binding and abrogate tumor suppressor activity in DLBCL and multiple myeloma, while promoter hypermethylation silences BCL7A in AML and CTCL; in the nervous system, BCL7A-containing BAF complexes regulate Notch/Wnt signaling and mitochondrial bioenergetics to support neural progenitor differentiation, Purkinje cell morphology, and cognitive flexibility."},"narrative":{"mechanistic_narrative":"BCL7A is a non-catalytic subunit of the mammalian SWI/SNF (BAF) chromatin remodeling complex that uses a highly conserved N-terminal domain to engage nucleosomes and modulate remodeling activity [PMID:32576963, PMID:41485079]. A conserved arginine anchor within its N-terminal α-helix is dispensable for integration into the complex but essential for BCL7A occupancy at target loci, for stimulating genome-wide occupancy of the BRG1 ATPase, and for histone displacement and chromatin accessibility, acting cooperatively with SMARCB1 to regulate canonical BAF remodeling [PMID:36305367, PMID:41485079]. Through this same N-terminal domain BCL7A also directly binds the transcription factor IRF4 to restrain its DNA-binding and transcriptional activity [PMID:40090008]. BCL7A functions as a tumor suppressor across multiple hematologic malignancies: splice-site or anchor mutations that disrupt the N-terminal domain prevent SWI/SNF binding and abolish tumor suppression in DLBCL [PMID:32576963, PMID:41485079], promoter hypermethylation silences BCL7A in AML where its restoration impairs proliferation and reduces cytarabine resistance [PMID:36941700, PMID:39053383], and loss of BCL7A in multiple myeloma de-represses IRF4 and promotes proliferation [PMID:40090008]. In the nervous system, BCL7A-containing BAF complexes are required non-redundantly for Purkinje cell morphology and motor behavior and for neural progenitor differentiation via regulation of Notch/Wnt signaling and mitochondrial bioenergetics [PMID:29213114, PMID:36305367]. First identified through a MYC-BCL7A fusion in a Burkitt lymphoma translocation, BCL7A defines a small gene family (BCL7A/B/C) conserved across metazoa whose homology is restricted to the N-terminal domain [PMID:8605326, PMID:9931421].","teleology":[{"year":1996,"claim":"Established BCL7A as a gene disrupted in lymphoma, first linking it to malignancy before any function was known.","evidence":"Molecular cloning and cDNA sequencing of a t(8;14;12) translocation producing a MYC-BCL7A fusion in a Burkitt lymphoma line","pmids":["8605326"],"confidence":"High","gaps":["No molecular function assigned","Caldesmon homology was sequence-based only and not functionally validated"]},{"year":1998,"claim":"Defined BCL7A as a member of a conserved gene family with homology confined to an N-terminal domain, focusing later mechanistic attention on this region.","evidence":"Sequence alignment, chromosomal mapping, and cross-species EST homology analysis","pmids":["9931421"],"confidence":"Medium","gaps":["No protein motifs identified outside the N-terminal domain","Function of the conserved domain not tested biochemically"]},{"year":2017,"claim":"Placed BCL7A inside the SWI/SNF complex in neurons and demonstrated a non-redundant in vivo requirement, distinguishing it from paralog BCL7B.","evidence":"Conditional and ubiquitous knockout mice with behavioral assays and Purkinje cell morphology analysis; BCL7B KO as control","pmids":["29213114"],"confidence":"High","gaps":["Molecular mechanism within SWI/SNF not resolved","Target genes driving the neural phenotype not identified"]},{"year":2020,"claim":"Showed that the N-terminal domain mediates SWI/SNF binding and that disrupting it abolishes tumor suppression, mechanistically connecting complex engagement to oncogenic loss-of-function.","evidence":"Splice-site mutation analysis, SWI/SNF binding assays, and BCL7A restoration in DLBCL in vitro and in vivo with transcriptomics","pmids":["32576963"],"confidence":"High","gaps":["Structural basis of binding not defined","Direct chromatin targets not mapped"]},{"year":2022,"claim":"Defined BCL7A's role as a modulator rather than structural component, stimulating BRG1 occupancy genome-wide and coupling chromatin remodeling to Notch/Wnt and mitochondrial programs.","evidence":"Conditional KO mice, genome-wide BRG1 ChIP-seq, NPC differentiation assays, and pharmacological rescue (Wnt agonist, pioglitazone)","pmids":["36305367"],"confidence":"High","gaps":["How BCL7A stimulates BRG1 occupancy mechanistically unresolved at this stage","Direct vs. indirect control of mitochondrial bioenergetics not separated"]},{"year":2023,"claim":"Identified promoter hypermethylation as an epigenetic silencing mechanism inactivating BCL7A in AML, extending its tumor-suppressor role beyond mutation.","evidence":"Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine treatment, cell competition and xenograft assays with differential expression analysis","pmids":["36941700"],"confidence":"High","gaps":["Downstream effectors (HMGCS1, H1-0, IRF7) not mechanistically linked to SWI/SNF activity","Whether silencing is a driver or passenger event not established"]},{"year":2024,"claim":"Added post-transcriptional regulation by PTBP1 and tied BCL7A restoration to apoptosis, differentiation, and reduced chemoresistance in AML.","evidence":"Overexpression/knockdown in AML lines, in vivo models, PTBP1 interaction studies, and IRF7/HMGCS1 expression analysis","pmids":["39053383"],"confidence":"Medium","gaps":["PTBP1 interaction not biochemically characterized","Mechanism by which BCL7A regulates IRF7/HMGCS1 unresolved"]},{"year":2025,"claim":"Revealed a direct, chromatin-independent activity: BCL7A binds IRF4 to limit its DNA binding, explaining tumor suppression in multiple myeloma.","evidence":"Whole-genome sequencing, BCL7A loss/gain-of-function in MM lines, direct BCL7A-IRF4 interaction assay, RNA-seq, and metabolic assays in vitro and in vivo","pmids":["40090008"],"confidence":"High","gaps":["Structural basis and binding interface of BCL7A-IRF4 not defined","Relationship between IRF4 inhibition and SWI/SNF function not integrated"]},{"year":2025,"claim":"Provided a structural framework for the BCL7 family as a dynamic tether linking the SWI/SNF ARP module to the nucleosomal acidic patch, with ATP hydrolysis modulating histone association.","evidence":"Cryo-EM of ncBAF-nucleosome complexes (nucleotide-free and bound), cross-linking mass spectrometry, and remodeling assays (preprint; resolves BCL7B, extrapolated to family)","pmids":["bio_10.1101_2025.11.20.689410"],"confidence":"Medium","gaps":["Preprint, not peer-reviewed","Structure is of BCL7B, not BCL7A directly","Direct ncBAF role of BCL7A not structurally confirmed"]},{"year":2026,"claim":"Pinpointed a conserved N-terminal arginine anchor as the functional element required for chromatin remodeling, occupancy, and tumor suppression, separating activity from complex integration.","evidence":"Structural prediction with arginine anchor mutagenesis, chromatin accessibility and ChIP occupancy assays, transcriptional analysis, and in vivo tumor suppression assays showing SMARCB1 cooperativity","pmids":["41485079"],"confidence":"High","gaps":["High-resolution structure of human BCL7A-nucleosome contact not solved","Mechanism of SMARCB1 cooperativity not detailed"]},{"year":null,"claim":"How BCL7A's two activities — nucleosome engagement within SWI/SNF and direct IRF4 inhibition — are coordinated, and whether they are separable in tumor suppression, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking chromatin remodeling and IRF4 sequestration","Tissue-specific determinants of which activity dominates not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[8,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,7,8]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[8,9]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,8]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,8]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,5,7]}],"complexes":["SWI/SNF (BAF)","canonical BAF (cBAF)","non-canonical BAF (ncBAF)"],"partners":["BRG1","SMARCB1","IRF4","PTBP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q4VC05","full_name":"B-cell CLL/lymphoma 7 protein family member A","aliases":[],"length_aa":210,"mass_kda":22.8,"function":"","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q4VC05/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL7A","classification":"Not Classified","n_dependent_lines":15,"n_total_lines":1208,"dependency_fraction":0.012417218543046357},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"ARID1A","stoichiometry":10.0},{"gene":"SMARCA4","stoichiometry":10.0},{"gene":"SMARCD1","stoichiometry":10.0},{"gene":"SMARCD2","stoichiometry":4.0},{"gene":"SMARCE1","stoichiometry":4.0},{"gene":"ACTG1","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BCL7A","total_profiled":1310},"omim":[{"mim_id":"605847","title":"BAF CHROMATIN REMODELING COMPLEX SUBUNIT BCL7C; BCL7C","url":"https://www.omim.org/entry/605847"},{"mim_id":"605846","title":"BAF CHROMATIN REMODELING COMPLEX SUBUNIT BCL7B; BCL7B","url":"https://www.omim.org/entry/605846"},{"mim_id":"601406","title":"BAF CHROMATIN REMODELING COMPLEX SUBUNIT BCL7A; BCL7A","url":"https://www.omim.org/entry/601406"},{"mim_id":"109565","title":"BCL6 TRANSCRIPTION REPRESSOR; BCL6","url":"https://www.omim.org/entry/109565"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BCL7A"},"hgnc":{"alias_symbol":["SMARCJ1"],"prev_symbol":["BCL7"]},"alphafold":{"accession":"Q4VC05","domains":[{"cath_id":"-","chopping":"3-49","consensus_level":"medium","plddt":87.9113,"start":3,"end":49}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q4VC05","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q4VC05-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q4VC05-F1-predicted_aligned_error_v6.png","plddt_mean":62.41},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL7A","jax_strain_url":"https://www.jax.org/strain/search?query=BCL7A"},"sequence":{"accession":"Q4VC05","fasta_url":"https://rest.uniprot.org/uniprotkb/Q4VC05.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q4VC05/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q4VC05"}},"corpus_meta":[{"pmid":"15897551","id":"PMC_15897551","title":"Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.","date":"2005","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15897551","citation_count":187,"is_preprint":false},{"pmid":"8605326","id":"PMC_8605326","title":"Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8605326","citation_count":86,"is_preprint":false},{"pmid":"18663754","id":"PMC_18663754","title":"Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF.","date":"2008","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18663754","citation_count":42,"is_preprint":false},{"pmid":"9931421","id":"PMC_9931421","title":"The BCL7 gene family: deletion of BCL7B in Williams syndrome.","date":"1998","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9931421","citation_count":39,"is_preprint":false},{"pmid":"32576963","id":"PMC_32576963","title":"Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL.","date":"2020","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/32576963","citation_count":38,"is_preprint":false},{"pmid":"36305367","id":"PMC_36305367","title":"BCL7A-containing SWI/SNF/BAF complexes modulate mitochondrial bioenergetics during neural progenitor differentiation.","date":"2022","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/36305367","citation_count":22,"is_preprint":false},{"pmid":"33415690","id":"PMC_33415690","title":"MiR-501-3p promotes osteosarcoma cell proliferation, migration and invasion by targeting BCL7A.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/33415690","citation_count":12,"is_preprint":false},{"pmid":"36941700","id":"PMC_36941700","title":"BCL7A is silenced by hypermethylation to promote acute myeloid leukemia.","date":"2023","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/36941700","citation_count":11,"is_preprint":false},{"pmid":"39053383","id":"PMC_39053383","title":"BCL7A inhibits the progression and drug-resistance in acute myeloid leukemia.","date":"2024","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/39053383","citation_count":10,"is_preprint":false},{"pmid":"29213114","id":"PMC_29213114","title":"The SWI/SNF subunit Bcl7a contributes to motor coordination and Purkinje cell function.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29213114","citation_count":10,"is_preprint":false},{"pmid":"40090008","id":"PMC_40090008","title":"Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma.","date":"2025","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/40090008","citation_count":7,"is_preprint":false},{"pmid":"41485079","id":"PMC_41485079","title":"BCL7A's arginine anchor links nucleosome recognition to chromatin remodeling and diffuse large B-cell lymphoma tumor suppression.","date":"2026","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/41485079","citation_count":0,"is_preprint":false},{"pmid":"41419953","id":"PMC_41419953","title":"MiR-328-5p/BCL7A axis is involved in fracture healing by modulating osteoblast function.","date":"2025","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/41419953","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.20.689410","title":"Structural basis for BCL7B-mediated ncBAF-nucleosome engagement","date":"2025-11-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.20.689410","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.17.612632","title":"Plant BCL-Domain Homologues play a conserved role in SWI/SNF complex stability","date":"2024-09-19","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.17.612632","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10035,"output_tokens":2852,"usd":0.036443,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10275,"output_tokens":3626,"usd":0.071013,"stage2_stop_reason":"end_turn"},"total_usd":0.107456,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"BCL7A was identified as a novel gene encoding a serine-rich protein of 231 amino acids with homology to the actin-binding protein caldesmon, discovered through molecular cloning of a three-way chromosomal translocation t(8;14;12) in a Burkitt lymphoma cell line where a MYC-BCL7A fusion transcript was produced with exon I of BCL7A replaced by MYC exon I.\",\n      \"method\": \"Molecular cloning, cDNA sequencing, Northern blot, sequence homology analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct molecular cloning, full cDNA sequencing, multiple breakpoints characterized; foundational discovery paper\",\n      \"pmids\": [\"8605326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BCL7A defines a gene family (BCL7A, BCL7B, BCL7C) sharing ~90% identity in an amino-terminal domain of ~51 amino acids, with orthologs in Drosophila melanogaster, C. elegans, and Brugia malayi, but no identified protein motifs were found outside this conserved N-terminal domain.\",\n      \"method\": \"Sequence alignment, chromosomal mapping, EST homology analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — sequence-based identification replicated across species and multiple family members; functional domain not yet validated biochemically\",\n      \"pmids\": [\"9931421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCL7A was identified as a subunit of the SWI/SNF complex in neurons; genetic deletion of BCL7A in postmitotic neurons in mice causes motor abnormalities and affects dendritic branching of Purkinje cells, while BCL7B knockout has no phenotype, demonstrating BCL7A's non-redundant role within SWI/SNF in neural function.\",\n      \"method\": \"Conditional and ubiquitous knockout mouse models, behavioral assays, neuronal morphology analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean in vivo KO with specific cellular phenotype (Purkinje cell morphology, motor behavior); BCL7B double-KO rules out redundancy\",\n      \"pmids\": [\"29213114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCL7A functions as a tumor suppressor in DLBCL by binding to the SWI/SNF complex via its amino-terminal domain; splice site mutations in intron 1 produce a truncated BCL7A protein that fails to bind the SWI/SNF complex and cannot suppress tumor growth, while restoration of wild-type BCL7A induces transcriptomic changes in B-cell activation genes.\",\n      \"method\": \"BCL7A restoration experiments, in vitro and in vivo tumor assays, splice site mutation analysis, SWI/SNF complex binding assays, transcriptome analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (in vitro/in vivo restoration, binding assay, transcriptomics), mechanistic link between truncation, complex binding failure, and loss of tumor suppression\",\n      \"pmids\": [\"32576963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCL7A modulates the SWI/SNF/BAF complex by stimulating genome-wide occupancy of the ATPase subunit BRG1; BCL7A is dispensable for SWI/SNF/BAF complex integrity but is essential for regulating Notch/Wnt pathway signaling and mitochondrial bioenergetics in differentiating neural progenitor cells (NPCs); pharmacological Wnt stimulation or mitochondrial biogenesis enhancement (pioglitazone) partially rescues BCL7A-deficient NPC phenotypes.\",\n      \"method\": \"BCL7A conditional knockout mice, genome-wide BRG1 occupancy (ChIP-seq), NPC differentiation assays, pharmacological rescue experiments, behavioral/cognitive testing\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional KO plus ChIP-seq occupancy data plus pharmacological rescue, multiple orthogonal methods establishing pathway position\",\n      \"pmids\": [\"36305367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BCL7A expression is silenced in AML by promoter hypermethylation (confirmed by methylation-specific PCR, bisulfite sequencing, and 5-aza-2'-deoxycytidine treatment); restoration of BCL7A expression in AML cell lines reduces competitive growth, decreases tumor growth in xenograft models, and alters cell cycle pathways and expression of HMGCS1, H1-0, and IRF7.\",\n      \"method\": \"Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine treatment, cell competition assay, xenograft mouse model, differential expression analysis\",\n      \"journal\": \"Biomarker research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic link between methylation-driven silencing and tumor suppressor function validated by multiple orthogonal methods including in vivo xenograft\",\n      \"pmids\": [\"36941700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCL7A acts as a tumor suppressor in AML and is negatively regulated post-transcriptionally by PTBP1; overexpression of BCL7A inhibits AML cell proliferation, induces apoptosis, promotes differentiation, and decreases cytarabine resistance by upregulating IRF7 and downregulating HMGCS1.\",\n      \"method\": \"BCL7A overexpression/knockdown in AML cell lines, in vivo mouse models, interaction studies with PTBP1, cell cycle/apoptosis/differentiation assays, IRF7/HMGCS1 expression analysis\",\n      \"journal\": \"Drug resistance updates\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional assays, single lab, PTBP1 interaction not fully characterized biochemically in the abstract\",\n      \"pmids\": [\"39053383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCL7A directly interacts with the transcription factor IRF4 (plasma cell-defining), limiting its DNA-binding activity; loss of BCL7A in multiple myeloma cells enhances IRF4-associated cytokine expression, reduces mitochondrial metabolism and reactive oxygen species levels, and promotes cell proliferation, establishing BCL7A as a tumor suppressor in MM.\",\n      \"method\": \"Whole-genome sequencing, BCL7A loss-of-function and ectopic expression in MM cell lines, in vitro and in vivo proliferation assays, protein-protein interaction assay (BCL7A–IRF4 direct interaction), RNA-seq, metabolic assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct protein-protein interaction plus in vitro/in vivo functional assays and transcriptomic/metabolic readouts; multiple orthogonal methods in a single study\",\n      \"pmids\": [\"40090008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"BCL7A contains a conserved arginine anchor in its N-terminal α-helix that is essential for chromatin remodeling activity of hSWI/SNF complexes; this anchor is required for BCL7A occupancy at target loci and chromatin accessibility/transcriptional regulation, but not for BCL7A integration into the complex; DLBCL-associated mutations in this anchor impair tumor suppressor function; mechanistically, BCL7A regulates histone displacement and works cooperatively with SMARCB1 to regulate canonical BAF (cBAF) remodeling activity.\",\n      \"method\": \"Protein structural prediction, mutagenesis of arginine anchor, in vivo and cellular tumor suppression assays, chromatin accessibility assays, transcriptional regulation analysis, ChIP occupancy assays\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural prediction with mutagenesis validation, in vivo assays, chromatin accessibility, and mechanistic epistasis with SMARCB1; multiple orthogonal methods\",\n      \"pmids\": [\"41485079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BCL7 proteins (including BCL7A) act as dynamic molecular tethers within the SWI/SNF ARP module, connecting it to the nucleosomal acidic patch; BCL7 proteins promote ncBAF-mediated nucleosome remodeling, and BRG1-catalyzed ATP hydrolysis triggers conformational changes that modulate BCL7-mediated histone association, as resolved by cryo-EM of ncBAF-nucleosome complexes in nucleotide-free and nucleotide-bound states. (Note: this preprint describes BCL7B specifically, but establishes a general BCL7 family mechanism.)\",\n      \"method\": \"Cryo-electron microscopy, biochemical assays, cross-linking mass spectrometry, nucleosome remodeling assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — cryo-EM structure with biochemical validation but preprint (not peer-reviewed); describes BCL7 family generally, BCL7B specifically; mechanism extrapolated to BCL7A\",\n      \"pmids\": [\"bio_10.1101_2025.11.20.689410\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"BCL7A is a non-catalytic subunit of the mammalian SWI/SNF/BAF chromatin remodeling complex that, via a conserved N-terminal arginine anchor, directly engages nucleosomes (interacting with the acidic patch) to stimulate genome-wide BRG1 ATPase occupancy and promote histone displacement and chromatin accessibility; its N-terminal domain also mediates a direct protein–protein interaction with IRF4 to restrict IRF4 transcriptional activity; splice-site or missense mutations disrupting this domain prevent SWI/SNF complex binding and abrogate tumor suppressor activity in DLBCL and multiple myeloma, while promoter hypermethylation silences BCL7A in AML and CTCL; in the nervous system, BCL7A-containing BAF complexes regulate Notch/Wnt signaling and mitochondrial bioenergetics to support neural progenitor differentiation, Purkinje cell morphology, and cognitive flexibility.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCL7A is a non-catalytic subunit of the mammalian SWI/SNF (BAF) chromatin remodeling complex that uses a highly conserved N-terminal domain to engage nucleosomes and modulate remodeling activity [#3, #8]. A conserved arginine anchor within its N-terminal \\u03b1-helix is dispensable for integration into the complex but essential for BCL7A occupancy at target loci, for stimulating genome-wide occupancy of the BRG1 ATPase, and for histone displacement and chromatin accessibility, acting cooperatively with SMARCB1 to regulate canonical BAF remodeling [#4, #8]. Through this same N-terminal domain BCL7A also directly binds the transcription factor IRF4 to restrain its DNA-binding and transcriptional activity [#7]. BCL7A functions as a tumor suppressor across multiple hematologic malignancies: splice-site or anchor mutations that disrupt the N-terminal domain prevent SWI/SNF binding and abolish tumor suppression in DLBCL [#3, #8], promoter hypermethylation silences BCL7A in AML where its restoration impairs proliferation and reduces cytarabine resistance [#5, #6], and loss of BCL7A in multiple myeloma de-represses IRF4 and promotes proliferation [#7]. In the nervous system, BCL7A-containing BAF complexes are required non-redundantly for Purkinje cell morphology and motor behavior and for neural progenitor differentiation via regulation of Notch/Wnt signaling and mitochondrial bioenergetics [#2, #4]. First identified through a MYC-BCL7A fusion in a Burkitt lymphoma translocation, BCL7A defines a small gene family (BCL7A/B/C) conserved across metazoa whose homology is restricted to the N-terminal domain [#0, #1].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established BCL7A as a gene disrupted in lymphoma, first linking it to malignancy before any function was known.\",\n      \"evidence\": \"Molecular cloning and cDNA sequencing of a t(8;14;12) translocation producing a MYC-BCL7A fusion in a Burkitt lymphoma line\",\n      \"pmids\": [\"8605326\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No molecular function assigned\", \"Caldesmon homology was sequence-based only and not functionally validated\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined BCL7A as a member of a conserved gene family with homology confined to an N-terminal domain, focusing later mechanistic attention on this region.\",\n      \"evidence\": \"Sequence alignment, chromosomal mapping, and cross-species EST homology analysis\",\n      \"pmids\": [\"9931421\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No protein motifs identified outside the N-terminal domain\", \"Function of the conserved domain not tested biochemically\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed BCL7A inside the SWI/SNF complex in neurons and demonstrated a non-redundant in vivo requirement, distinguishing it from paralog BCL7B.\",\n      \"evidence\": \"Conditional and ubiquitous knockout mice with behavioral assays and Purkinje cell morphology analysis; BCL7B KO as control\",\n      \"pmids\": [\"29213114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism within SWI/SNF not resolved\", \"Target genes driving the neural phenotype not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed that the N-terminal domain mediates SWI/SNF binding and that disrupting it abolishes tumor suppression, mechanistically connecting complex engagement to oncogenic loss-of-function.\",\n      \"evidence\": \"Splice-site mutation analysis, SWI/SNF binding assays, and BCL7A restoration in DLBCL in vitro and in vivo with transcriptomics\",\n      \"pmids\": [\"32576963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of binding not defined\", \"Direct chromatin targets not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined BCL7A's role as a modulator rather than structural component, stimulating BRG1 occupancy genome-wide and coupling chromatin remodeling to Notch/Wnt and mitochondrial programs.\",\n      \"evidence\": \"Conditional KO mice, genome-wide BRG1 ChIP-seq, NPC differentiation assays, and pharmacological rescue (Wnt agonist, pioglitazone)\",\n      \"pmids\": [\"36305367\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BCL7A stimulates BRG1 occupancy mechanistically unresolved at this stage\", \"Direct vs. indirect control of mitochondrial bioenergetics not separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified promoter hypermethylation as an epigenetic silencing mechanism inactivating BCL7A in AML, extending its tumor-suppressor role beyond mutation.\",\n      \"evidence\": \"Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine treatment, cell competition and xenograft assays with differential expression analysis\",\n      \"pmids\": [\"36941700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors (HMGCS1, H1-0, IRF7) not mechanistically linked to SWI/SNF activity\", \"Whether silencing is a driver or passenger event not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Added post-transcriptional regulation by PTBP1 and tied BCL7A restoration to apoptosis, differentiation, and reduced chemoresistance in AML.\",\n      \"evidence\": \"Overexpression/knockdown in AML lines, in vivo models, PTBP1 interaction studies, and IRF7/HMGCS1 expression analysis\",\n      \"pmids\": [\"39053383\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PTBP1 interaction not biochemically characterized\", \"Mechanism by which BCL7A regulates IRF7/HMGCS1 unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed a direct, chromatin-independent activity: BCL7A binds IRF4 to limit its DNA binding, explaining tumor suppression in multiple myeloma.\",\n      \"evidence\": \"Whole-genome sequencing, BCL7A loss/gain-of-function in MM lines, direct BCL7A-IRF4 interaction assay, RNA-seq, and metabolic assays in vitro and in vivo\",\n      \"pmids\": [\"40090008\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis and binding interface of BCL7A-IRF4 not defined\", \"Relationship between IRF4 inhibition and SWI/SNF function not integrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Provided a structural framework for the BCL7 family as a dynamic tether linking the SWI/SNF ARP module to the nucleosomal acidic patch, with ATP hydrolysis modulating histone association.\",\n      \"evidence\": \"Cryo-EM of ncBAF-nucleosome complexes (nucleotide-free and bound), cross-linking mass spectrometry, and remodeling assays (preprint; resolves BCL7B, extrapolated to family)\",\n      \"pmids\": [\"bio_10.1101_2025.11.20.689410\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not peer-reviewed\", \"Structure is of BCL7B, not BCL7A directly\", \"Direct ncBAF role of BCL7A not structurally confirmed\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Pinpointed a conserved N-terminal arginine anchor as the functional element required for chromatin remodeling, occupancy, and tumor suppression, separating activity from complex integration.\",\n      \"evidence\": \"Structural prediction with arginine anchor mutagenesis, chromatin accessibility and ChIP occupancy assays, transcriptional analysis, and in vivo tumor suppression assays showing SMARCB1 cooperativity\",\n      \"pmids\": [\"41485079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structure of human BCL7A-nucleosome contact not solved\", \"Mechanism of SMARCB1 cooperativity not detailed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BCL7A's two activities \\u2014 nucleosome engagement within SWI/SNF and direct IRF4 inhibition \\u2014 are coordinated, and whether they are separable in tumor suppression, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking chromatin remodeling and IRF4 sequestration\", \"Tissue-specific determinants of which activity dominates not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 7, 8]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 8]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 8]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 5, 7]}\n    ],\n    \"complexes\": [\"SWI/SNF (BAF)\", \"canonical BAF (cBAF)\", \"non-canonical BAF (ncBAF)\"],\n    \"partners\": [\"BRG1\", \"SMARCB1\", \"IRF4\", \"PTBP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}